Search
forLearn
5 / 801 resultslearn enoxolone
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn Viniferine
learn Naltrexone
Research
5 / 1000+ results
research Combined drug triads for synergic neuroprotection in retinal degeneration
Using three different drugs together may better treat eye diseases like glaucoma and macular degeneration.
research Repurposing of Various Current Medicines as Radioprotective Agents
Some existing medicines show promise as safe treatments to protect against the side effects of radiation therapy.
research Minoxidil suppressed mitochondrial depolarization and subsequent neuronal cell death by decreasing intracellular potassium level
Minoxidil may protect the brain from damage by preventing cell death and energy loss.
research A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
Avacopan may cause unexpected side effects, so early monitoring is important.
research Deep Insight of Design, Mechanism, and Cancer Theranostic Strategy of Nanozymes
Nanozymes show promise for effective and safe cancer treatment.
Community Join
5 / 1000+ resultscommunity Thoughts on Avixis Alfatradiol?
Avixis Alfatradiol is a topical 5-alpha reductase inhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community Rejected for the 2nd time for the VDPHL01 Clinical Trials (believe it or not!)
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community Pyrilutamide available at Actifolic now
Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.